Physician profile
William J Read
NPI 1053361311
$3,629.41
in general payments reported to CMS, 2019-2025
19 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $384 · 2021: $191 · 2022: $389 · 2023: $774 · 2024: $685 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $725.87 | 2019-2025 | Rocklatan, Argos, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $349.91 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $308.45 | 2024-2025 | Xdemvy |
| Abbvie INC. | $285.93 | 2022-2025 | |
| Oyster Point Pharma, INC. | $285.53 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $257.66 | 2019-2021 | |
| Biotissue Holdings INC. | $213.92 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $213.21 | 2020-2023 | |
| Glaukos Corporation | $192.28 | 2019-2023 | |
| Omeros Corporation | $184.13 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $150.28 | 2019-2021 | |
| Allergan, INC. | $142.26 | 2019-2022 | |
| Alimera Sciences, INC. | $93.85 | 2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $76.52 | 2024 | Syfovre |
| Shire North American Group INC | $41.85 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $36.70 | 2024-2025 | Dextenza |
| Rayner Intraocular Lenses Limited | $36.32 | 2022 | |
| Thea Pharma INC. | $20.93 | 2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $13.81 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Read listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.